Slide - Anesthesiology - American Society of Anesthesiologists

Comments

Transcription

Slide - Anesthesiology - American Society of Anesthesiologists
From: Antagonism of Nerve Growth Factor-TrkA Signaling and the Relief of Pain
Anesthes. 2011;115(1):189-204. doi:10.1097/ALN.0b013e31821b1ac5
Figure Legend:
Fig. 4.
Therapies that sequester nerve growth factor (NGF) or inhibit tropomyosin-related kinase A receptor (TrkA)
demonstrate significant analgesic efficacy in mouse and a human model of nonmalignant skeletal pain. In a mouse model of bone
fracture, pain-related behaviors (the time spent guarding of the fractured limb during a 2-min observation) were significantly reduced
by anti-NGF therapy (10 mg/kg, intraperitoneal, administered at d 1, 6, and 11 after fracture) (A
Date of download:
Copyright
© 2017 American
Society
of Anesthesiologists.
All rights
reserved.
) and8/12/2017
the pan-Trk antagonist
ARRY-470
(30 mg/kg,
oral, administered
twice daily
beginning
on d 1 after fracture) (B

Similar documents